A Multi-Center, Open-Label, Randomized Phase 3 Trial Comparing the Safety and efficacy of 177Lu-PSMA-I&T versus Hormone Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer
Study of Lutetium-177 PSMA I&T in Patients with Castration-Resistant Prostate Cancer
Sponsor: Curium
Enrolling: Male Patients Only
IRB Number: AAAU2918
U.S. Govt. ID: NCT05204927
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: This study is being done to learn if the study drug called Lutetium-177 PSMA I&T is safe and effective in patients with castration-resistant metastatic prostate cancer. The study drug contains radioactive Lutetium-177, which is targeted to treat certain prostate cancers cells that have a protein called the prostate-specific membrane antigen (PSMA) on the surface of the prostate cancer cells. Not all cancer cells have PSMA on their surface. This targeted approach has the potential of treating the cancerous cells with radiation while limiting the radiation exposure to the healthy parts of your body. This study is the first study the sponsor has conducted in humans, although the study drug has been used in over a thousand patients outside of the United States on a compassionate use basis in patients with metastatic prostate cancer the study drug is not FDA approved.
This study is closed
Mark Stein, MD
Do You Qualify?
Are you at least 18 years old? Yes No
Have you been diagnosed with prostate cancer? Yes No
Have you had previous treatment with next-generation androgen receptor (AR)-directed therapy (e.g. abiraterone, enzalutamide)? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator